


PHARMACEUTICAL 2019

Myovant Sciences Ltd. Rank 296 of 363





PHARMACEUTICAL 2019

Myovant Sciences Ltd. Rank 296 of 363

The relative strengths and weaknesses of Myovant Sciences Ltd. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Myovant Sciences Ltd. compared to the market average is the variable Liabilities, Non-Current, increasing the Economic Capital Ratio by 14% points. The greatest weakness of Myovant Sciences Ltd. is the variable Research and Development, reducing the Economic Capital Ratio by 71% points.

The company's Economic Capital Ratio, given in the ranking table, is -78%, being 115% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	114,763
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	37,085
Liabilities, Non-Current	0
Other Assets	3,065
Other Compr. Net Income	-116
Other Expenses	2,259
Other Liabilities	44,287
Other Net Income	67
Other Revenues	0
Property and Equipment	1,273
Research and Development	116,832
Selling, General and Administrative Expense	24,231

Output Variable	Value in 1000 USD
Assets	119,101
Liabilities	81,372
Expenses	143,322
Revenues	0
Stockholders Equity	37,729
Net Income	-143,255
Comprehensive Net Income	-143,313
Economic Capital Ratio	-78%

